Abstract
Elevated Soluble Suppressor of Tumorigenicity 2 Levels in Gout Patients and Its Association with Cardiovascular Disease Risk Indicators
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have